BEIJING, Sept. 3, 2010 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that its annual general meeting will be held at 9 am Beijing Time on September 30, 2010 at No. 18-1 East Nanping Road, Hunnan National New & High-tech Development Zone, Shenyang, Liaoning Province, China P.R. China.
The primary agenda of the meeting is to re-elect Mr. Huining Cao as the Company's director and to appoint Ernst & Young Hua Ming as independent auditor of the Company for the fiscal year ending December 31, 2010.
Only shareholders of record at the close of business on September 2, 2010 are entitled to receive notice and to vote at the annual general meeting and any adjournment. Holders of the Company's American Depository Shares who wish to exercise their voting rights for the underlying shares must act through the depository. Shareholders are cordially invited to attend the annual general meeting.
A notice of the annual general meeting describing the matters to be considered at the meeting is available online at . The Company's annual report for the year ended December 31, 2009 is also available online.
Shareholders of China Nuokang may receive a hard copy of 20-F free of charge upon request. Please send e-mail request to email@example.com and provide your complete mailing and contact details.
About China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 2,400 hospitals in China. Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share, and Aiduo®, a cardiovascular stress imaging agent. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit www.nkbp.com for more information.
CONTACT: ICR, LLC In the U.S.: Ashley M. Ammon Christine Duan 1-646-277-1227 In China: Wen Lei Zheng 86-10-6599-7968